NCT06731101

Brief Summary

The aim of the study is to compare between ganglion block versus combined oral anticholinergic and antidepressant drugs on treatment of palmar hyperhidrosis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 9, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 12, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

January 15, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2025

Completed
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

February 6, 2026

Status Verified

February 1, 2026

Enrollment Period

11 months

First QC Date

December 9, 2024

Last Update Submit

February 4, 2026

Conditions

Palmar Hyperhidrosis

Keywords

Stellate ganglion block

Outcome Measures

Primary Outcomes (1)

  • Secretions

    i.e. presence/absence of hyperhidrosis

    3 months

Secondary Outcomes (1)

  • Compensatory hyperhidrosis

    1 ]week

Study Arms (2)

Stellate ganglion block

ACTIVE COMPARATOR

bupivacaine+ lidocaine + dexamethasone injection into stellate ganglion

Drug: Bupivacaine + Lidocaine +dexamethasone

Drugs

ACTIVE COMPARATOR

librax + tryptizole

Drug: Tryptizole + Librax

Interventions

Bupivacaine + Lidocaine +dexamethasoneDRUG

Sonar guided block of Stellate Ganglion By Bupivacaine + Lidocaine

Also known as: xylocaine or bupivacine, lidocaine or marcaine
Stellate ganglion block
Tryptizole + LibraxDRUG

Tryptizole + Librax

Also known as: Anxiolytics
Drugs

Eligibility Criteria

Age20 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age from 20 to 45 years.
  • Both genders.

You may not qualify if:

  • \. An inability of patient to cooperate. 2. Known allergies to anticholinergic or antidepressant drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taha mohamed agmy

Al Fayyum, 084, Egypt

Location

MeSH Terms

Interventions

BupivacaineLidocainechlordiazepoxide, clidinium drug combinationAnti-Anxiety Agents

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesAcetanilidesTranquilizing AgentsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesCentral Nervous System AgentsTherapeutic UsesPsychotropic Drugs

Study Officials

  • Atef M Khalil, professor

    Fayoum University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Compare two groups of Palmar hyperhidrosis one with injection Local anesthetic at stellate ganglion, the other will take oral medication
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Atef Mohamed Mahmoud

Study Record Dates

First Submitted

December 9, 2024

First Posted

December 12, 2024

Study Start

January 15, 2025

Primary Completion

December 10, 2025

Study Completion

January 1, 2026

Last Updated

February 6, 2026

Record last verified: 2026-02

Locations

EG(1)